Recently, Zhejiang Hongrui Medical Technology Co., Ltd. (hereinafter referred to as "Hongrui Medical") announced the completion of the first stage financing of the 10-million-level pre-A round, which was led by Taizhou Jiaojiang Yingfei Haizheng Fund under Infinity Capital. This round of financing will be mainly used for the optimization of tumor organ construction, the research and development of supporting automatic instruments and equipment, reagent consumables and the construction of third-party clinical laboratories.

Hongrui Medical, founded in 2021, is an innovative medical science and technology enterprise with tumor organ construction technology as its core. The founder of the company, Professor Luo Guoan, is also one of the pioneers of microfluidic technology in China. The research team led by him has carried out research on microfluidic technology in biomedicine for more than 20 years, successfully built a highly integrated and automated bionic microfluidic chip experimental platform, developed a variety of new models of microfluidic organ chips, and provided a reliable experimental platform and in vitro innovation for drug efficacy and safety evaluation.

Patient-derived tumor organoids (PDO) refers to the removal of cancer cells from patients (surgery, extraction of malignant effusion or biopsy), and the cultivation of micro-organs with three-dimensional structure in vitro by simulating the microenvironment in vivo in the laboratory, thus forming the "body double" of tumors. Tumor organs are highly similar to patients' own tumor tissues in both genetic background and histological characteristics. As the "body double of drug testing" for patients, tumor organs have the characteristics of high throughput and easy operation. In a short time (two weeks on average), the sensitivity test results of chemotherapy drugs, targeted drugs, monoclonal antibodies and combined drugs are obtained, which will strive for more valuable treatment time for tumor patients with no drugs available and multiple drugs available, and provide more accurate data support for the formulation of personalized medication plans.

Hongrui Medical has successfully established organ-like culture and drug sensitivity detection systems for 15 kinds of high-incidence malignant tumors and their metastatic lesions, including lung cancer, liver cancer, gastric cancer, colorectal cancer, esophageal cancer, nasopharyngeal cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, renal cancer, etc., and has been continuously increased and improved. The company's clinical laboratory has obtained the practice license of medical institutions and can carry out clinical laboratory services for cancer patients.

The company successfully built a highly integrated and automated bionic microfluidic chip experimental platform and developed a variety of new models of microfluidic organ chips. Based on microfluidic chip technology, an organ-like chip system for liver tissue microstructure and microenvironment simulation was successfully built, which can be used to evaluate drug hepatotoxicity. The micro-physiological environment of various organs, including oxygen gradient micro-environment, hardness gradient micro-environment and mechanical force micro-environment, can be simulated efficiently on the microfluidic chip. And successfully constructed a variety of three-dimensional organ structures such as liver sphere, liver acinar model and glomerular model on the chip.

The fully automatic operating instruments and equipment, intelligent operating system and reagent consumables independently developed by the company reduce human operation errors, have high throughput, meet the screening requirements, and produce drug sensitivity test results quickly, which guarantees the success rate, stability and clinical relevance of tumor organs and has strong competitiveness in the industry. Hongrui Medical's philosophy is to contribute to improving the success rate and survival rate of cancer patients in China.

Taizhou Jiaojiang Infineon Haizheng Fund is jointly funded by Taizhou Asset Management Co., Ltd., Zhejiang Haizheng Pharmaceutical Co., Ltd., Jiaojiang District Government Industrial Fund and Infinity (Zhuhai) Venture Capital Management Co., Ltd., with Infinity Capital as the manager, with a fund scale of 500 million RMB. The fund is positioned to invest in "medical health" industries, focusing on projects in the fields of biomedicine and high-value medical consumables in the life sciences.